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Abstract
Background: There are few previous reports regarding the cause and evolution of liver injury in patients with
anorexia nervosa (AN) during the refeeding process, and its management remains controversial. This study aimed to
determine the risk factors for elevated liver enzymes during refeeding and their effect on the therapeutic process in
severely malnourished patients with eating disorders.
Methods: In a retrospective cohort study of 167 female inpatients in a single hospital from January 2004 to March
2015, 67 who had normal alanine aminotransferase (ALT) levels on admission were divided into two groups
according to the presence or absence of elevated ALT levels during refeeding, and then compared.
Results: The median age and body mass index (BMI) of the patients on admission were 22 [interquartile range (IQR),
16–33] years and 12.2 (IQR, 11.1–13.0) kg/m2, respectively. Compared with their cohorts, significantly more patients in
the early onset age group (<15 years old) had elevated ALT levels during refeeding (67% vs. 33%, p = 0.033), as did
patients with longer median time to nadir BMI (3.0 vs. 0 days, p = 0.03). In addition, onset age [odds ratio (OR): 0.274;
95% confidence interval (CI): 0.077–0.981; p = 0.047] and time to nadir BMI (OR: 1.271; 95% CI: 1.035–1.56; p = 0.022)
were significantly associated with the odds of elevated ALT levels during refeeding.
Conclusions: The results of this study suggest that early age at onset may be a potential risk factor for elevated ALT
levels during refeeding in severely malnourished patients with eating disorders. Furthermore, elevated ALT levels
during refeeding were significantly associated with delay in the start of weight gain. No significant relationship was
found between the amount of initial prescribed calories and elevated ALT levels during refeeding. The median time to
maximum ALT was 27 (IQR, 21–38) days after the refeeding process started.
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Plain English summary
Refeeding is a therapeutic process for malnourished pa-
tients with eating disorders. The development of elevated
liver enzymes during this process often becomes a clinical
issue. Previous studies report that liver enzymes may be-
come elevated as a result of either the body becoming ema-
ciated or the refeeding process itself. The focus of this
study was on the refeeding process. The results suggest that
early onset age is a potential risk factor for the development
of elevated liver enzymes during refeeding. Furthermore,
we found that delay in the start of weight gain may be asso-
ciated with elevated liver enzymes during refeeding. The
amount of initial calorie intake did not have a negative ef-
fect on liver dysfunction during refeeding in this study.
Background
Weight restoration and nutritional rehabilitation are
fundamental steps in the treatment program for patients
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with anorexia nervosa (AN) [1]. The prolonged state of
starvation in patients with AN increases cognitive distor-
tion and complicates both commencement of therapy
and cooperation during treatment. In addition, the phys-
ical condition of patients with AN often deteriorates,
leading to a critical illness. The initial and most crucial
goal of treatment is to break such patients out of the vi-
cious cycle of weight loss and cognitive distortion by
helping them recover weight and improve their nutri-
tional condition [2]. The eventual goals of nutritional re-
habilitation for seriously malnourished patients with AN
are to restore weight, normalize eating patterns, achieve
normal perceptions of hunger and satiety, and correct
the biological and psychological sequelae of malnutrition
[1]. However, the development of elevated liver enzymes
during refeeding often becomes a clinical issue during
the therapeutic process. Although rare, there are reports
of patients with AN who developed marked fatty liver
accumulation, leading to fatal hepatic failure [3], or who
developed liver injury with hypoglycemic coma during
refeeding [4].
The precise mechanisms involved in the pathogenesis of
elevated liver enzymes in patients with AN have yet to be
clearly defined. However, recently, a multifactorial etiology
has been hypothesized. Hepatocellular injuries associated
with non-alcoholic fatty liver disease have been regarded
as a cause of elevated liver enzymes in patients with AN
and those recovering from malnutrition [3, 5, 6]. Some re-
ports have presented the relationship between low body
mass index (BMI) and hepatocellular injuries [7–11]. Sug-
gested etiologies include acute liver hypoperfusion [12,
13], hepatic steatosis with oxidative stress [6], and
starvation-induced hepatocyte autophagy [14, 15].
Conversely, mild-to-moderate liver enzyme elevation
is common in patients with AN during the refeeding
process [7, 16]. Liver enzyme elevation during refeeding
may pose a dilemma for clinicians when deciding
whether to delay the progressive increase in caloric in-
take. Progression of refeeding may worsen liver injury,
but there is evidence that faster weight gain predicts year
1 weight recovery [17]. To our knowledge, the only pub-
lished data related to this problem show that the initial
prescribed caloric intake may be associated with elevated
liver enzymes during refeeding [10]. Little remains
known about the causes and optimal management of el-
evated liver enzymes in clinical practice.
Therefore, the objectives of the present study were to
clarify the risk factors for elevated liver enzymes during
refeeding in severely malnourished patients with eating
disorders and to reveal their effects on the process of
nutritional rehabilitation. To achieve these objectives,
we retrospectively analyzed clinical variables in a rela-
tively large cohort of severely underweight patients with
eating disorders.
Methods
This study was conducted with the following objectives: 1)
to identify potential risk factors associated with the devel-
opment of elevated liver enzymes during refeeding from
among the patients’ background characteristics, blood bio-
chemical findings on admission, and the amount and
speed of caloric intake during hospitalization; and 2) to
examine whether the development of elevated liver en-
zymes during refeeding affects the therapeutic course (e.g.,
duration of hospitalization, ratio of BMI increase, and
time to nadir BMI during the hospitalization).
Study population
This retrospective observation study included 304 patients
who were admitted to the Psychiatry Department of Na-
goya University Hospital in Nagoya, Japan between 1
January 2004 and 31 March 2015 for nutritional rehabili-
tation, and who fulfilled the following inclusion criteria: 1)
a diagnosis of anorexia nervosa–restricting type (AN-R),
anorexia nervosa–binge-eating/purging type, avoidant/re-
strictive food intake disorder, or other specified feeding or
eating disorder, according to the Diagnostic and Statistical
Manual of Mental Disorders, Fifth Edition (DSM-5) [18];
2) a duration of hospitalization longer than 14 days; 3)
blood and laboratory data recorded at least twice; and 4) a
BMI of less than 15 kg/m2 on admission.
Exclusion criteria included the following: 1) male sex, as
97% (295/304) of the patients were female; 2) patients with
positive serological tests for hepatitis B or C on admission;
3) patients with a history of hepatic disease or drug or alco-
hol abuse; and 4) patients with insufficient clinical data.
After applying these exclusion criteria, 167 patients were
selected. Two psychiatrists (MI and ST) used the DSM-5
criteria to re-diagnose those patients who had been diag-
nosed before 2013 using the DSM-IV-TR.
Refeeding protocol
As a rule, nutritional rehabilitation therapy at Nagoya
University Hospital was commenced using oral feeding. A
high-calorie liquid dietary supplement was administered
to replenish the daily caloric intake of patients with insuf-
ficient oral intake. Enteral refeeding by nasogastric tube
was additionally used for patients who had insufficient
weight gain or frequent episodes of hypoglycemia. A num-
ber of patients presented with severe malnutrition (BMI
<12 kg/m2) on admission. In such cases, refeeding was
started gradually with the administration of 500–
1000 kcal/day, in consideration of the amount of energy
intake prior to admission. Refeeding was followed by a
progressive increase of 200 kcal every 3 days, according to
the patient’s clinical status, with an objective of 1 kg of
weight gain per week. In our hospital ward, bringing any
medications, such as laxatives, into the room is strictly
prohibited, and patients are thoroughly searched.
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Moreover, patients eat in the day room under supervision
and are required to stay there for an hour after eating to
control their purging behavior. Fundamentally, nutritional
rehabilitation therapy was based on the American Psychi-
atric Association Practice Guidelines [1]. Twelve of 167
patients received parenteral nutrition because of difficul-
ties with oral or enteral feeding.
Study design
The demographic and clinical data reported in the present
study were obtained retrospectively by electronic chart re-
view for each patient on admission, and included the fol-
lowing: age; age of illness onset; duration of illness; weight;
height; blood biochemical data; and the amount of caloric
intake during the refeeding process. In our hospital, height
is measured on admission. Weight is also measured on ad-
mission and twice a week using a strict protocol: under
supervision, patients are required to urinate or defecate,
change into a hospital gown, and step onto a scale after a
body check to confirm that they do not have anything to
falsify their body weight. In the case of patients who drank
an excessive amount of water, we also examine laboratory
data around the same time to confirm the presence of
overhydration [suggested by the presence of dilutional
hyponatremia, dilutional anemia, and low blood urea ni-
trogen (BUN) level]. If patients were admitted to Nagoya
University Hospital more than once, data from the first
hospitalization were used. Medical charts were reviewed
independently by a psychiatrist (MI) and a dietician (SK),
and a further evaluation of clinical parameters, including
diagnosis and age of illness onset, was conducted by two
psychiatrists (MI and ST) experienced in treating eating
disorders.
Clinical parameters analyzed included the following:
duration of hospitalization; BMI on admission; BMI on
discharge; ratio of BMI increase (BMI on discharge/BMI
on admission); speed of BMI increase, calculated as
[(BMI on discharge – BMI on admission)/duration of
hospitalization]; nadir BMI during hospitalization; time
to nadir BMI; initial prescribed calories/kg; maximum
prescribed calories/kg; and speed of caloric increase,
calculated as [(maximum prescribed calories – initial
prescribed calories)/days to maximum prescribed
calories]. As a rule, we examine the first serum chemis-
tries before refeeding on admission. After refeeding ther-
apy is started, blood is drawn every day or every third
day as clinically indicated. When the general condition
of the patients is stabilized, blood is drawn once a week
during hospitalization. Routine laboratory data obtained
on admission included the following: total protein (TP);
albumin; glucose; BUN; creatinine; aspartate amino-
transferase (AST); alanine aminotransferase (ALT); lac-
tate dehydrogenase; alkaline phosphatase; gamma
glutamyl transferase; white blood cells; red blood cells;
hemoglobin, hematocrit; and platelets. BMI was calcu-
lated as weight in kilograms divided by the square of
height in meters (kg/m2).
ALT is a specific measure of liver injury [19], so we
determined that any elevation in ALT from baseline was
a sign of liver injury, and regarded it as a symptom of
liver damage. ALT >27 IU/L was considered elevated ac-
cording to the upper limit of the normal level used by
the Nagoya University Hospital laboratory.
First, the enrolled patients were divided into two
groups according to the presence or absence of elevated
ALT levels on admission (Fig. 1). Next, we selected the
67 patients who had normal ALT levels on admission for
inclusion in the study, and excluded those with elevated
ALT levels on admission, which was probably associated
with starvation before refeeding. The 67 patients with
normal ALT levels on admission were then categorized
into the following two groups: 1) Group A, who had
normal ALT levels during refeeding (N = 35); and 2)
Group B, who had elevated ALT levels during refeeding
(N = 32). Eight patients (three from Group A and five
from Group B) who received total parenteral nutrition
(TPN) were excluded because TPN was started later as
the need arose, and because it involves different meta-
bolic pathways than oral or enteral feeding. Finally, 59
patients receiving oral and/or tube feeding comprised
the final groups, categorized as Group A (normal ALT
levels during refeeding; N = 32) and Group B (elevated
ALT levels during refeeding; N = 27). Patients in Group
A had normal ALT levels throughout hospitalization,
while patients in Group B presented with normal ALT
levels on admission and then developed elevated ALT
levels during refeeding. Groups A and B were then
compared using the previously described clinical
parameters.
Statistical analysis
Univariate statistics were used to describe the sample,
including frequency (%), range, and median [interquar-
tile range (IQR)]. We used Mann-Whitney U tests to
compare the medians of continuous variables (such as
age) and chi-square tests to compare the proportions of
categorical variables (such as onset age) between groups.
Multivariate analysis using logistic regression was per-
formed with the presence of elevated ALT levels during
refeeding as the dependent variable. The independent
variables included BMI on admission, initial prescribed
calories (which was considered clinically important in a
previous report) [10], and factors identified by univariate
analysis. Values of p < 0.05 were considered statistically
significant. All statistical analyses were performed using
the Statistical Package for Social Sciences (SPSS) (ver.
23, IBM, Armonk, NY).
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Results
Patients’ characteristics
During the 11 years and 3 months of the study
period, 304 patients with eating disorders from 500
total hospitalizations were admitted to the Psychiatry
Department of Nagoya University Hospital, 65% of
whom were admitted only once. After applying the
exclusion criteria, 167 patients were eligible for inclu-
sion in this study. The patients had a median age of
22 (IQR, 16–33) years and a median illness onset age
of 17 (IQR, 14–20) years (Table 1). The median BMI
on admission was 12.2 (IQR, 11.1–13.0) kg/m2, and
the median amount of initial prescribed calories was
37.1 (IQR, 27.7–50.3) kcal/kg. In total, 92% (154/167)
of the patients were diagnosed with AN, and more
than half (55%; 92/167) were diagnosed with AN-R.
Based on category definitions used in previous reports
[20, 21], of the 167 patients, 28% (N = 47) were in the
early onset age (<15 years old) group; 60% (N = 100)
were in the peak onset age (15–24 years old) group;
and 12% (N = 20) were in the late onset age (≥25 years
old) group. The median duration of hospitalization
was 58 (IQR, 36–82) days, with the longest stay being
285 days.
Blood biochemical findings of all enrolled patients on
admission are shown in Table 2. A total of 100 (60%) pa-
tients had elevated ALT levels on admission (Fig. 1),
while 132 (79%) had elevated ALT levels at some point
during hospitalization. Of the 67 patients with normal
ALT levels on admission, 32 (48%) developed elevated
ALT levels during refeeding.
Maximum ALT levels of the patients in Group B
ranged over 28–347 IU/L, with a median of 41 (IQR,
36–79) IU/L, indicating mild-to-moderate elevation [19].
The median time to maximum ALT in Group B was 27
(IQR, 21–38) days, with the longest time being 72 days
(Fig. 2). Elevated ALT levels in Group B peaked 27 days
after the refeeding process started.
Among the patients in Group B, 81% (22 of 27)
had follow-up ALT data showing a decrease to the
normal range after approximately 1 month [median,
28 (IQR, 10–54) days] from the date of maximum
Fig. 1 Enrollment flow chart. ALT, alanine aminotransferase; TPN, total parenteral nutrition
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ALT. On the other hand, 7% (2 of 27) had continued
ALT elevation after 1 month from the date of max-
imum ALT (data not shown).
Comparison of groups A and B
Results from a comparison of Groups A and B are
shown in Tables 3 and 4. The number of patients in the
early onset age group was significantly higher in Group
B than in Group A. The number of patients in the peak
onset and late onset groups was significantly higher in
Group A than in Group B (χ2(1) = 4.56, p = 0.033, φ =
0.28). The median time to nadir BMI was significantly
longer in Group B than in Group A (3 days vs. 0 days,
U = 302.5, p = 0.03, r = 0.28). No significant differences
were found between the two groups in age, BMI on ad-
mission, duration of illness, or initial prescribed calories.
TP was significantly lower in Group B than in Group A
(6.6 vs. 7.1 g/dL, U = 293, p = 0.034, r = 0.28).
Risk factors related to elevated ALT levels during
refeeding
To identify the most important risk factors for elevated
ALT levels during refeeding, multivariate analysis using
logistic regression was performed with the following four
factors (Table 5): onset age; BMI on admission; time to
nadir BMI; and initial prescribed calories. As for onset
age, a dummy-coded variable (early onset age group = 0,
peak or late onset age group = 1) was used. Onset age
[odds ratio (OR): 0.274; 95% confidence interval (CI):
0.077–0.981; p = 0.047] and time to nadir BMI (OR:
Table 1 Patients’ characteristics (N = 167)
Median (IQR) Range
Age (years) 22 (16–33) 10–54
Age of illness onset (years) 17 (14–20) 8–45
Duration of illness (years) 2.2 (1.0–11.0) 0.2–40.0
Duration of hospitalization (days) 58 (36–82) 15–285
BMI on admission (kg/m2) 12.2 (11.1–13.0) 8.1–14.9
BMI on discharge (kg/m2) 14.6 (13.9–15.3) 11.3–18.5
Ratio of BMI increasea 1.2 (1.1–1.3) 1.0–1.8
Speed of BMI increase ([kg/m2]/days)b 0.04 (0.03–0.05) 0–0.13
Minimum BMI during hospitalization
(kg/m2)
11.9 (10.8–12.8) 8.1–14.6
Time to nadir BMI (days) 2 (0–6) 0–43
Initial prescribed calories (kcal/kg) 37.1 (27.7–50.3) 5.9–115.3
Maximum prescribed calories (kcal/kg) 69.6 (57.3–80.7) 29.5–125.0






Early onset (<15 years old) 47 (28)
Peak onset (15–24 years old) 100 (60)
Late onset (≥25 years old) 20 (12)
IQR interquartile range, BMI body mass index, AN-R anorexia nervosa–
restricting type, AN-BP anorexia nervosa–binge-eating/purging type, ARFID
avoidant/restrictive food intake disorder, OSFED other specified feeding or
eating disorder, BW body weight
aRatio of BMI increase, BMI on discharge/BMI on admission; bSpeed of BMI
increase: (BMI on discharge–BMI on admission)/duration of hospitalization;
cSpeed of caloric increase: [(maximum prescribed calories–initial prescribed
calories)]/days to maximum prescribed calories
Table 2 Blood biochemical findings on admission (N = 167)
Median (IQR) Range
TP (6.7–8.3 g/dL)a 6.6 (6.1–7.1) 4.3–8.4
Albumin (4–5 g/dL) 4.2 (3.9–4.7) 1.9–5.5
Glucose (70–109 mg/dL) 76 (67–88) 20–166
BUN (8–22 mg/dL) 15 (11–23) 4–60
Creatinine (0.4–0.7 mg/dL) 0.6 (0.5–0.7) 0.2–1.5
AST (13–33 IU/L) 32 (23–62) 5–2881
ALT (6–27 IU/L) 33 (20–86) 6–2751
LDH (119–229 IU/L) 227 (184–304) 112–746
ALP (115–359 IU/L) 193 (140–263) 24–1163
GGT (10–47 IU/L) 29 (16–57) 8–423
WBC (3.8–8.5 × 103/μL) 3.8 (3.0–4.7) 1.2–14.1
RBC (3.6–5.0 × 106/μL) 3.98 (3.59–4.32) 2.02–5.53
Hemoglobin (11–16 g/dL) 12.3 (11.4–13.3) 7.4–17.9
Hematocrit (32–48%) 36.5 (33.9–39.5) 21.5–47.3
Platelets (160–410 × 103/μL) 201 (156–245) 34–566
IQR interquartile range, TP total protein, BUN blood urea nitrogen, AST
aspartate aminotransferase, ALT alanine aminotransferase, LDH lactate
dehydrogenase, ALP alkaline phosphatase, GGT gamma glutamyl transferase,
WBC white blood cells, RBC red blood cells
aReference range shown in parentheses
Fig. 2 Timing and magnitude of maximum ALT levels for patients in
Group B (N = 27). ALT, alanine aminotransferase. Patients in Group B
had elevated ALT levels (>27 IU/L) during refeeding
Imaeda et al. Journal of Eating Disorders  (2016) 4:37 Page 5 of 10
1.271; 95% CI: 1.035–1.56; p = 0.022) were significantly
associated with the risk of elevated ALT levels during
refeeding.
Discussion
In the present study, we examined the risk factors for el-
evated liver enzymes during refeeding in severely mal-
nourished patients with eating disorders, as well as the
effects on the nutritional rehabilitation process. We
found that early onset was significantly associated with
the development of elevated ALT levels during refeeding.
Time to nadir BMI was also significantly associated with
elevated ALT levels during refeeding (Tables 3 and
Table 5). However, no associations were found between
elevated ALT levels during refeeding and variations in
the refeeding method, including amount of initial pre-
scribed calories, maximum prescribed calories, and
speed of caloric increase (Table 3).
Early onset age as a risk factor for ALT elevation
To our knowledge, this is the first study to report that
early illness onset may be a risk factor for elevated ALT
levels during refeeding. One previous study that examined
predictors of elevated liver enzymes after admission in pa-
tients with AN did not mention the involvement of onset
age [10]. The basal metabolic rate among females is high-
est in the 12–14-year-old age group (1410 kcal/day), and
gradually declines with age [22]. Moreover, younger pa-
tients with AN may suffer more metabolic damage from
nutritional deficiencies [8] or have increased susceptibility
to liver damage [23]. The liver plays a central role in regu-
lating energy homeostasis through glucose, lipid, and pro-
tein metabolism [24]. Early onset of AN is likely to
damage the liver through nutrient deficiencies during the
growth process, resulting in some degree of vulnerability
thereafter.
According to a previous report, some children with
non-alcoholic fatty liver disease are at risk for developing
nonalcoholic steatohepatitis [25]. Although there is a dif-
ference in clinical conditions between fatty liver caused
by starvation and that by obesity, a similar pathogenetic
mechanism is hypothesized [24]. Therefore, we think it
is reasonable to be concerned with the long-term liver
pathology associated with early onset AN.
Concerning methods of refeeding
In the present study, no significant relationship was found
between the amount of initial prescribed calories and ele-
vated ALT levels. This result was different from those of a
previous report showing an association between initial
prescribed calories and elevated liver enzymes after admis-
sion [10]. That study used regression analysis that in-
cluded age, % median BMI on admission, and duration of
illness as variables. We speculate that the difference may
Table 3 Comparison of Group A and Group B (patients’ characteristics)
Group A Group B
N = 32 N = 27
Median (IQR) Range Median (IQR) Range p valuea
Age (years) 19 (16–30) 11–46 30 (15–37) 10–54 0.322
Age of illness onset (years) 16 (15–18) 11–35 17 (13–21) 8–38 0.957
Duration of illness (years) 1.6 (0.8–12.5) 0.2–28.0 9.0 (1.0–16.0) 0.5–40.0 0.132
Duration of hospitalization (days) 46 (29–76) 15–138 48 (34–75) 23–154 0.568
BMI on admission (kg/m2) 12.2 (11.1–13.3) 9.2–14.3 12.3 (10.8–13.2) 8.1–14.9 0.831
BMI on discharge (kg/m2) 14.6 (13.6–15.0) 11.3–18.5 14.6 (13.9–16.1) 11.4–17.4 0.548
Ratio of BMI increasec 1.2 (1.1–1.3) 1.0–1.5 1.2 (1.1–1.3) 1.1–1.6 0.389
Speed of BMI increase ([kg/m2]/days)d 0.04 (0.03–0.05) 0.02–0.13 0.05 (0.03–0.07) 0.01–0.13 0.159
Minimum BMI during hospitalization (kg/m2) 12.0 (10.9–12.8) 9.2–14.0 12.2 (10.8–13.2) 8.1–14.4 0.749
Time to nadir BMI (days) 0 (0–1.8) 0–10.0 3.0 (0–6.0) 0–41.0 0.03
Initial prescribed calories (kcal/kg) 37.0 (29.7–47.2) 6.6–77.2 33.2 (27.4–48.2) 16.7–115.3 0.67
Maximum prescribed calories (kcal/kg) 71.8 (56.5–82.8) 47.1–113.1 67.2 (58.5–82.7) 43.0–116.5 0.927
Speed of caloric increase (kcal/days)e 36.6 (29.4–59.6) 0–98.3 33.3 (14.6–63.8) 0–595.0 0.721
Frequency (%) p valueb
Early onset (<15 years old) 6 (33) 12 (67) 0.033
Peak or late onset (≥15 years old) 26 (63) 15 (37)
Patients in Group A had normal ALT levels (≤27 IU/L) during refeeding, while patients in Group B had elevated ALT levels (>27 IU/L) during refeeding
ALT alanine aminotransferase, IQR interquartile range, BMI body mass index, BW body weight
cRatio of BMI increase: [BMI on discharge/BMI on admission]; dSpeed of BMI increase: [(BMI on discharge–BMI on admission)/duration of hospitalization]; eSpeed of
caloric increase: [(maximum prescribed calories–initial prescribed calories)/days to maximum prescribed calories]; aMann-Whitney U test; bPearson chi-square test
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be attributable to the fact that the patients in the previous
study were younger than those in the present study [mean
± standard deviation, 16.1 ± 2.4 years vs. median, 22 (IQR,
16–33) years, respectively], and the amount of initial pre-
scribed calories was larger [mean, 1452.4 kcal vs. median,
1040 (IQR, 750–1600) kcal, respectively]. Therefore, both
younger age and higher initial prescribed calories may be
risk factors for elevated liver enzymes in patients with AN.
Another possible reason for this difference is that we re-
duced the initial prescribed calories because our partici-
pants had lower BMIs on admission than patients in the
previous study [median, 12.2 (IQR, 11.1–13.0) kg/m2 vs.
mean, 15.9 ± 1.9 kg/m2], as well as more severe emaciation
with more serious general physical deterioration.
The present study showed that 46% (27/59) of the
patients who had normal ALT levels on admission devel-
oped elevated ALT levels during refeeding. Conversely,
an earlier study showed that patients who did not have
hyperaminotransferasemia on admission retained normal
liver function during 4 weeks of refeeding [9]. One rea-
son for this might be that the amount of initial pre-
scribed calories in that study was lower than that in the
present study (maximum, 30 kcal/kg vs. median,
37.1 kcal/kg); in addition, those patients had less liver
damage. Another possibility is that the researchers only
considered that there was significant hepatic cytolysis
when AST and/or ALT levels were more than twice the
upper limit of the normal value. The different cutoff
points used might account for these mixed results. Since
few studies on liver dysfunction in patients with AN
during refeeding have been conducted, further studies
will be needed to adequately address this issue.
As previously mentioned, none of the nutritional
rehabilitation methods in the present study were associ-
ated with elevated liver enzymes during refeeding. The
median amount of initial prescribed calories was 37.1
(IQR, 27.7–50.3) kcal/kg, and the median amount of
maximum prescribed calories was 69.6 (IQR, 57.3–80.7)
kcal/kg. We could not investigate alteration of refeeding
in this study. We can only say, therefore, that the
volume of caloric intake within these ranges did not
have a negative effect on liver function. There are few
reports regarding the effect of refeeding strategy on liver
injury in patients with AN and further investigation is
needed. Moreover, it appears that matters such as inher-
ent characteristic traits related to liver injury and liver
Table 4 Comparison of Group A and Group B (blood biochemical findings on admission)
Group A Group B
N = 32 N = 27
Median (IQR) Range Median (IQR) Range p valueb
TP (6.7–8.3 g/dL)a 7.1 (6.8–7.5) 5.2–8.3 6.6 (6.4–7.1) 5.9–7.9 0.034
Albumin (4–5 g/dL) 4.6 (3.9–4.9) 2.1–5.3 4.3 (3.7–4.7) 2.7–5.3 0.125
Glucose (70–109 mg/dL) 78 (71–92) 34–132 83 (71–93) 51–121 0.558
BUN (8–22 mg/dL) 14 (12–17) 6–34 13 (9–15) 6–39 0.138
Creatinine (0.4–0.7 mg/dL) 0.64 (0.60–0.70) 0.48–1.24 0.62 (0.54–0.71) 0.26–1.35 0.398
AST (13–33 IU/L) 20 (18–25) 13–63 25 (22–31) 18–56 0.004
LDH (119–229 IU/L) 189 (160–211) 146–272 196 (157–242) 129–370 0.659
ALP (115–359 IU/L) 179 (130–224) 74–514 195 (141–241) 24–758 0.518
GGT (10–47 IU/L) 14 (11–27) 8–109 19 (14–35) 8–120 0.198
WBC (3.8–8.5 × 103/μL) 4.5 (3.8–5.0) 2.4–6.6 3.8 (3.1–5.2) 2.1–9.6 0.161
RBC (3.6–5 × 106/μL) 4.1 (3.8–4.4) 2.6–5.4 3.9 (3.5–4.2) 3.1–5.5 0.128
Hemoglobin (11–16 g/dL) 12.3 (11.5–13.4) 8.1–16.4 11.9 (11.1–13.1) 9.4–16.1 0.349
Hematocrit (32–48%) 36.7 (35.0–40.1) 24.5–47.3 35.8 (33.1–38.6) 28.9–45.5 0.283
Platelets (160–410 × 103/μL) 216 (188–254) 154–396 207 (175–260) 150–490 0.732
Patients in Group A had normal ALT levels (≤27 IU/L) during refeeding, while patients in Group B had elevated ALT levels (>27 IU/L) during refeeding
ALT alanine aminotransferase, IQR interquartile range, TP total protein, BUN blood urea nitrogen, AST aspartate aminotransferase, LDH lactate dehydrogenase,
ALP alkaline phosphatase, GGT gamma glutamyl transferase, WBC white blood cells, RBC red blood cells
aReference range shown in parentheses. bMann-Whitney U test
Table 5 ORs for determinants of normal or elevated ALT levels
during refeeding
Multivariate
OR (95% CI) p value
Onset age 0.274 (0.077–0.981) 0.047
BMI on admission (kg/m2) 0.857 (0.578–1.271) 0.442
Time to nadir BMI (days) 1.271 (1.035–1.56) 0.022
Initial prescribed calories (kcal/kg) 1.001 (0.969–1.034) 0.961
OR odds ratio, CI confidence interval, ALT alanine aminotransferase, BMI body
mass index
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vulnerability caused by early age of illness onset before
the start of refeeding therapy should be carefully
considered.
Elevated ALT levels may relate to delay in the start of
weight gain
In the present study, we found that elevated ALT levels
during refeeding were significantly associated with delay
in the start of weight gain; to our knowledge, this is the
first study to report this finding. We considered the
following three possible explanations.
First, the central feature of protein-energy malnutri-
tion such as kwashiorkor and marasmus malnutrition,
like AN, is edema [26]. Patients who had normal ALT
levels on admission and elevated ALT levels during
refeeding, and those who had a trend of lower TP on ad-
mission, may have had more clinically severe edema
than those who had normal ALT levels throughout their
hospitalization. It is therefore possible that after refeed-
ing started, patients with elevated ALT levels had in-
creased urination, which led to a decrease in body
weight and delay in the start of weight gain. A previous
study showed that refeeding edema developed more fre-
quently in patients with severely elevated liver enzymes
[11]. There may be a decrease in liver protein synthesis
associated with edema. If we assume the presence of
edema in our cohort, we can hypothesize that weight
loss at the initial stage of refeeding after prolonged star-
vation might predict elevation of liver enzymes in the
later stage.
A second possibility is that metabolic derangements
can occur during the process of refeeding in at-risk pa-
tients [27]. Weight gain is not expected to occur during
the first 5–7 days of refeeding because this period,
termed the “phase of stabilization”, is the period during
which a change from a catabolic to an anabolic state oc-
curs [28]. Delay in the start of weight gain among pa-
tients with elevated ALT levels during refeeding might
reflect the fact that this metabolic change imposes a
strain on the entire body, including the liver; given our
findings relevant to the association between delay in the
start of weight gain and subsequent ALT elevation, it
could be assumed that delay in the start of weight gain
may be a risk factor for elevated liver enzymes during
refeeding.
Finally, it is possible that the amount of caloric intake
was less than that required for weight gain, which led to
a decrease in weight. Prolonged starvation might cause
an emaciation-induced elevation in aminotransferase [7].
Therefore, weight gain or loss during initial nutritional
therapy may help distinguish elevated liver enzymes re-
lated to refeeding from those related to a state of starva-
tion [16]. Among patients with elevated ALT levels
during refeeding, most (25 of 27) had elevated liver
enzymes while gaining weight, so it is unlikely that pro-
longed starvation caused the elevation of liver enzymes.
Based on these findings, it is reasonable to assume that
several factors triggered by nutritional rehabilitation
contributed to the development of elevated liver
enzymes.
Liver injury during refeeding
Similar to a previous study that showed refeeding-
induced aminotransferase elevation [7], the present
study found that patients with elevated liver enzymes
during refeeding had mild-to-moderate ALT elevations
that peaked around the 27th day of hospitalization
(Fig. 2). This is consistent with previous findings show-
ing that the period from the nadir of body weight to the
peak of the aminotransferase elevation was about
20 days, and that the elevated ALT levels during refeed-
ing was milder than that of the emaciation-induced type,
accompanied by higher body weight and better physical
condition [7]. The reason why the number of days re-
quired to reach maximum ALT was greater in our study
than in the previous study may be that while we counted
from the first day of hospitalization to the point of peak
ALT, the previous results were calculated from the point
of nadir body weight to the point of peak ALT. Taken as
a whole, the finding of elevated liver enzymes among the
patients in Group B during refeeding was similar to that
of the previous study. Several hypotheses have been sug-
gested concerning the etiology of these abnormalities,
including excessive dextrose calories leading to fat accu-
mulation in the liver cells (hepatic steatosis) [27, 29, 30].
Among the patients in Group B, 81% (22 of 27) had
follow-up ALT data showing a decrease to the normal
range after approximately 1 month [median, 28 (IQR,
10–54) days] from the date of maximum ALT (data not
shown). It can therefore be said that the evolution of ele-
vated ALT levels was favorable in the same way as that
observed in TPN-related steatosis [31]. On the other
hand, the follow-up ALT data showed that 7% (2 of 27)
had continued ALT elevation after 1 month from the
date of maximum ALT. There is a case report of a
patient with AN who had a long duration of illness and
developed malnutrition-related nonalcoholic steatohepa-
titis [32]. As far as we know, there is no study on the
long-term prognosis of liver injury in patients with AN.
This issue deserves further research.
Limitations
The major limitations of this study are its retrospective
nature and its inability to prove causality. This study is
based on medical chart review, and we were unable to
review the data from physical examinations, including
the degree of edema. Furthermore, our study sample was
limited to severe and hospitalized cases; therefore, the
Imaeda et al. Journal of Eating Disorders  (2016) 4:37 Page 8 of 10
present findings cannot be generalized to outpatient or
community samples. Another limitation of the study is
that it did not evaluate liver histopathology or morph-
ology using ultrasonography, computed tomography,
and magnetic resonance imaging as the basis for
diagnosis.
Nutritional rehabilitation was performed under super-
vision in our structured ward; however, we cannot say
that purging behaviors were controlled perfectly. There
may have been a difference between the actual amount
of consumed calories and the administered amount in
some patients. As for body weight measurement, we
could not exclude the data of possibly overhydrated pa-
tients. Therefore, the present results include some influ-
ence from temporary fluctuations in body weight.
In addition, we were unable to exclude patients with ele-
vated liver enzymes who were receiving medication. Nine-
teen of 32 patients in Group A and 19 of 27 patients in
Group B were taking medications, including antidepres-
sants, major and minor tranquilizers, and hypnotics. In
multivariate analysis, we added medication use as an inde-
pendent variable and confirmed that the results for both
groups were identical; onset age (OR: 0.151; 95% CI:
0.033–0.697; p = 0.015) and time to nadir BMI (OR: 1.296;
95% CI: 1.042–1.613; p = 0.02) were significantly associ-
ated with the risk of elevated ALT levels during refeeding.
Further research using a protocol in which the effect of
medication is excluded would be useful.
Conclusions
In the present study, we aimed to identify the risk fac-
tors for elevated liver enzymes during refeeding in se-
verely underweight patients with eating disorders, as
well as the effects on the nutritional rehabilitation
process. We found that an early age of onset was signifi-
cantly associated with the development of elevated ALT
levels during refeeding. No associations were found be-
tween elevated ALT levels during refeeding and varia-
tions in the refeeding method, including initial
prescribed calories, maximum prescribed calories, and
speed of caloric increase. However, a significant relation-
ship was found between elevated ALT levels during
refeeding and time to nadir BMI; i.e., elevated ALT levels
during refeeding was significantly associated with delay
in the start of weight gain. The median time to max-
imum ALT was 27 (IQR, 21–38) days after the refeeding
process started.
Little previous research has been conducted concern-
ing liver enzyme elevation during refeeding in patients
with AN, and consensus regarding the pathophysio-
logical mechanisms involved or the best management
approach has yet to be reached. It is hoped that the re-
sults of this exploratory study will lead to more defini-
tive results from prospective studies in the future.
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